CD19 and pancreatic neoplasm: Both CD19 CAR-macrophage and mesothelin CAR-macrophage showed the ability to phagocytose CD19-expressing K562 leukemia cells and increased phagocytosis activity against mesothelin-expressing OVCAR3/ASPC1 ovarian/pancreatic cancer cells, respectively.